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Crossing survival curves complicate how we interpret results from a clinical trial’s primary endpoint. We find
the function to determine a crossing point’s location depends exponentially on individual survival curves. This
exponential relationship between survival curves and the crossing point transforms small survival curve errors
into large crossing point errors. In most cases, crossing points are sensitive to individual survival errors and may
make accurately locating a crossing point unsuccessful. We argue more complicated analyses for mitigating
crossing points should be reserved only after first exploring a crossing point’s variability, or hypothesis tests
account for crossing point variability.
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2I. INTRODUCTION
Crossing survival curves challenge how a treatment benefits patients compared to control therapy [1–5]. While past research
explores making decisions in light of crossing survival curves [6–15], little research explores crossing point uncertainty. We
derive a crossing point equation and discover how small errors estimating two survival curves propagate to large differences in
crossing points.
Past work adapts routine statistical tests to manage crossing survival curves. Supremum methods build statistics around the
largest survival difference between arms [8, 9]. Combination techniques estimate and join survival differences before and after
an assumed crossing point [6, 7]. Weighting methods apply weights to events that occur before or after a crossing point, and
typically shift attention away from survival differences before a crossing point and towards later survival differences [13, 14].
Newer statistical techniques, such as restricted mean survival [16], study different survival attributes that don’t as easily fall
prey to crossing points. Past work spends time mitigating the effect of crossing points without specifically addressing how two
survival curves cross.
In the following, we study (i) where two Weibull-distributed curves cross and define an analytical expression for a crossing
point, (ii) how errors estimating each survival parameter affect errors estimating a crossing point, (iv) determine survival curve
characteristics that lead to difficulty estimating a crossing point, and (v) compare parameter estimate errors versus crossing point
errors as a function of sample size.
II. METHODS
We derive a formula identifying when two survival curves cross (tχ) and establish this function sensitively depends on all
four survival curve parameters (2 parameters for the treatment population and 2 parameters for the control population). We
find errors demonstrate power law and exponential properties (Fig.1), increasing similarity between survival curves increases
crossing point uncertainty (Fig.2 & Fig.3), and while an increasing sample size decreases survival curve parameter errors at a
similar rate, crossing point errors depend on survival curve characteristics (Fig.4).
II.1. Crossing-point equation
Consider each treatment arm’s survival distributed Weibull with failure distributed
p(T < t|λ, k) = α(t|λ, k) = e−(λt)k .
We find where two survival curves (one from the treatment group α1(t) and a second from the control group α0(t)) cross by
setting them equal and solving for t. The crossing point (tχ) equals
tχ = exp
(
−k1 log(λ1)− k0 log(λ0)
k1 − k0
)
(1)
where λx represents the survival’s failure parameter, kx represents a survival’s shape parameter, and we identify the treatment
group as x = 1 and control group as x = 0. This equation shows us two survival curves (i) will not cross with equal shapes k,
(ii) will not cross with divergent failures λ, and (iii) errors in either survival curve will propagate to errors in the crossing point’s
location.
II.2. Crossing point sensitivity
We derived a simple formula relating a crossing point to individual survival curves, and study how errors in estimating a
survival curve can cause errors locating a crossing point. The  error a parameter p contributes to a relative error in tχ is defined
as
R(|p) = tχ()/tχ − 1. (2)
We can determine how sensitively a crossing point depends on λ and k and fundamental quantities related to crossing point
sensitivity by studying how crossing point errors scale with these two parameters.
Using (2) and relative to λ, we find tχ’s error scales like
R(φ|λ) ∼
∣∣∣∣∣∣
(
1
1 + φ
)(1− k0k1 )−1 ∣∣∣∣∣∣
3where φ represents a percent error in λ (defined as  = φ × λ). We see λ’s influence on tχ scales like a power law with
exponent equal to the relative difference between survival curve shapes 1− k0k1 . A larger relative difference between ks shrinks
λ’s influence on tχ.
Relative to k, a crossing point’s error scales like
R(φ|k) ∼
∣∣∣∣∣∣
(
λ1
λ0
)φ[(1− k0k1 )( k1k0−1)]−1∣∣∣∣∣∣
where φ represents a percent error in k. Errors from k depend on the relative difference between shape parameters and the ratio
between failures λ1 and λ0. We found two quantities, the relative difference between shape parameters
(
1− k0k1
)
and ratio of
failures
(
λ1
λ0
)
, play key roles in generating crossing point errors.
Considering a simple empirical example with the treatment group’s 365 (730) day failure rate equal to 10% (18%) and control
group’s 365 (730) day failure rate equal to 10% (20%), we see small errors made estimating both λ and k cause large errors
locating a crossing point (Fig.1A.). Producing λ or k values 10% different than the true parameter values could inflate tχ’s error
by as much as 100%. Exploring how errors in λ relate to tχ (Fig.1B.), this power law relationship quickly inflates small λ errors
into notable tχ errors. Measurement errors in k exponentially amplify tχ errors (Fig.1C.).
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FIG. 1. We see the crossing point (tχ) function (1) amplifies the shape parameter (k) and failure parameter (λ)’s estimation errors (A.), and
the relative difference between survival curve shapes (B.) and ratio between failures (C.) key components driving crossing point error.
Errors from λ and k to tχ depend on properties of our system. We can consider the errors from λ to tχ and from k to tχ as
functions of these system level properties.
We consider λ’s error function as
R(γ|φ, λ) ∼
∣∣∣∣∣∣
(
1
1 + φ
)(1− 1γ )−1∣∣∣∣∣∣ ,
depending on γ = k1k0 and fixed φ. Increasing γ away from 1 decreases tχ’s error due to φ (errors in λ) (Fig.2B.). A larger
relative difference between shape parameters causes the two survival curves to meet at a steeper angle (Fig.2A.) and dampen
errors.
We consider k’s error function as
R(γ|φ, k) ∼
∣∣∣∣(λ0tχ)[(1−γ)( 1φ+ 11+γ−1 )]−1 ∣∣∣∣
depending on γ, and decreasing steeply as γ moves away from 1 (Fig.3C.) or as the two survival curve shapes become more
distinct (Fig.3A.). We can also consider k’s error function as
R(z|φ, k) ∼
∣∣∣z[( 11+r )( 1φr−1)]−1 ∣∣∣ (3)
r =
log (λ0tχ)
log(z)
,
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FIG. 2. Increasing the relative difference between shape parameters (ks) causes the two survival curves to cross at a steeper angle (A.). The
relative error the failure parameter (λ) contributes to the crossing point (tχ) decreases as the relative difference between shapes increases (B.).
with z = λ1λ0 , and decreasing as z moves away from 1 (Fig.3D.) or as the patient’s event probability separates (Fig.3B.).
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FIG. 3. Contrasting λs and ks between survival curves lower the error k transfers to tχ. A larger difference between ks result in more sudden
crossings (A.). Larger difference between survival shapes decreases the relative error k contributes to tχ (C.). Larger differences between λs
also force survival curves to cross at sharper angles (B.) and decrease the relative error k contributes to tχ (D.)
We find the underlying properties of the patient population and event under study controls how well we can estimate a crossing
point. More contrasted survival curve shapes or survival curve failure rates allow us to better estimate crossing points. Even with
dissimilar survival curve properties, small changes in survival curve parameter cause large swings in where two curves cross.
This crossing point sensitivity will manifest from drawing a finite sample and estimating individual parameters for treatment and
control patient populations.
III. STATISTICAL INFERENCE
With a data sample, we first estimate each survival curve’s shape and scale, and second estimate the crossing point. Assuming
the Weibull distribution generated our survival data, we estimate the shape and failure’s posterior probability as
p(λ, k|D) ∝ p(D|λ, k)× p(λ, k),
or log posterior probability
log (p(λ, k)) ∝ (E + α− 1) log(k) + (kE + γ − 1) log(λ) + (k − 1)
E∑
i=1
log(ti) −
λk N∑
j=1
tki + βk + ηλ

5with E events, N patients, N − E censored observations, gamma-distributed prior probability p(k) = β
α
Γ(α)
kα−1e−βk, and
gamma-distributed prior probability p(λ) =
ηγ
Γ(γ)
kγ−1e−ηk.
We simulated N control patients and N treatment patients from N = 200 to N = 1900. For each sample size, our control
population’s shape equaled k0 = 1.08 and failure equaled λ0 = 3.43 × 10−4. The treatment population’s shape and failure
was set to four scenarios; two scenarios set the relative difference between treatment and control failures to 25% and 50%, and
the remaining two scenarios set the relative difference between treatment and control’s shape to 25% and 50%. We fixed the
crossing point for all the above scenarios to tχ = 365 days.
Although our parameter estimates relative error shrinks at the same rate regardless of the true (λ1, k1), the crossing point’s
relative error depends on the true (λ1, k1) and increases when either the true k1 lies closer to k0 or true λ1 lies closer to λ0. As
our sample size N grows from 200 patients to 1900 patents, we find both λ and k’s relative error quickly shrinks toward zero
percent independent of λ or k’s true value (Fig.4A. and Fig.4B.). Opposing this parameter-independent shrinking, the crossing
point’s estimated error depends on the λ and k’s true value. Supporting our above theory, we find lower relative errors in the
crossing point with more separate failures (Fig.4B.) and shapes (Fig.4D.).
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FIG. 4. As our sample size grows, uncertainty in parameters decreases independently of their true values (A. & C.), while the error locating
the crossing point depends on the true shape and failure values (B. & D.). (A.) A 10-simulation average relative error in λ from 200 to 1900
patients. (B.) The crossing point’s average relative error caused by λ. (C.) A 10-simulation average relative error in k from 200 to 1900
patients. (D.) The crossing point’s average relative error caused by k.
IV. DISCUSSION
The event and population we study influence (λ, k) and determine how certain we can estimate a crossing point. Two survival
curves with similar shapes or failure parameters amplify small errors into considerable crossing point errors. Before using more
sophisticated hypothesis tests, one should consider how the event type and patients under study affect crossing point sensitivity
and impact conclusions from hypothesis tests.
Previous work does not consider crossing point uncertainties and this may cause overconfident results from hypothesis tests.
If we consider the probability each event in a sample occurs after a crossing point, previous work assigns either a probability
of 0 or 1. Weighting methods too conservatively devalue events before the assumed crossing point (assigning them probability
0) and over-value events after the assumed crossing point (assigning them probability 1). Combination methods that analyze
survival differences before and after an assumed crossing point make similar oversights. Choosing a specific point to analyze
survival differences could underestimate variances by not accounting for events moving between groups caused by an uncertain
(moving) crossing point.
This crossing point analysis was limited to Weibull-like survival curves. Weibull distributions can flexibly model events with
increasing or decreasing hazards through time, but cannot handle more complicated hazard functions. Composite endpoints
pose a significant challenge due to a mixture of early and late events, and the above may not appropriately handle these types of
events.
Future work will focus on non-parametric alternatives to estimating crossing points (Weibull-free) and measuring the impact
crossing points outside the time interval of interest have on analysis, and examining how hypothesis tests that handle crossing
6points over confidently make conclusions. A non-parametric method to estimate crossing points may better handle non-Weibull
distributions and composite endpoints. While we studied crossing points within a highlighted time interval, locating where two
curves cross will effect models that assume proportional hazards. Evaluating hypothesis tests that assume an exact crossing point
will allow us to develop better tests that do not draw overconfident conclusions.
We should study survival curve characteristics and crossing point uncertainty before turning to more complicated hypothesis
tests. A more intense study of a crossing point may save investigators from complicated interpretations and lead to simpler more
impactful messages.
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